Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Nov 8:2017:bcr2017221065.
doi: 10.1136/bcr-2017-221065.

Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia

Sanah Sajawal  1 , Sarah L Mackie  2 , Peter Hillmen  3 , Dennis McGonagle  4
Affiliations
Case Reports

Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia

Sanah Sajawal et al. BMJ Case Rep. .

Abstract

We report a patient with chronic lymphocytic leukaemia (CLL) who was treated with idelalisib, a PI3Kδ inhibitor with rituximab. After 20 weeks of treatment, the patient developed classical signs and symptoms of polymyalgia rheumatica (PMR) in association with an elevated C reactive protein of 74 mg/L. After 2 weeks of prednisolone 15 mg daily symptoms had resolved and acute phase markers normalised. To our knowledge, this is the first report of PMR developing as a complication of PI3Kδ inhibitor treatment of CLL.

Keywords: haematology (drugs And Medicines); musculoskeletal syndromes.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

See all similar articles

References

    1. Mackie SL, Mallen CD. Polymyalgia rheumatica. BMJ 2013;347:f6937 10.1136/bmj.f6937 - DOI - PubMed
    1. Dejaco C, Singh YP, Perel P, et al. . 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2015;74:1799–807. 10.1136/annrheumdis-2015-207492 - DOI - PubMed
    1. Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, et al. . The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 2000;27:2179–84. - PubMed
    1. Yang Q, Modi P, Newcomb T, et al. . Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clin Cancer Res 2015;21:1537–42. 10.1158/1078-0432.CCR-14-2034 - DOI - PMC - PubMed
    1. Brown JR, Byrd JC, Coutre SE, et al. . Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123:3390–7. 10.1182/blood-2013-11-535047 - DOI - PMC - PubMed

Publication types

MeSH terms